The Top 10 Largest Biopharma M&A Deals in 2020
AstraZeneca/Alexion Pharmaceuticals
Deal value: $39 billion
Premium to previous closing price: 45%
Date announced: Dec. 12, 2020
Gilead Sciences/Immunomedics
Deal value: $21 billion
Premium to previous closing price: 108%
Date announced: Sept. 13, 2020
Bristol Myers Squibb/MyoKardia
Deal value: $13.1 billion
Premium to previous closing price: 61%
Date announced: Oct. 5, 2020
Johnson & Johnson/Momenta Pharmaceuticals
Deal value: $6.5 billion
Premium to previous closing price: 70%
Date announced: Aug. 19, 2020
Gilead Sciences/Forty Seven
Deal value: $4.9 billion
Premium to previous closing price: 65%
Date announced: March 2, 2020
Sanofi/Principia Biopharma
Deal value: $3.68 billion
Premium to previous closing price: 10%
Date announced: Aug. 17, 2020
Merck & Co./VelosBio
Deal value: $2.75 billion
Premium to previous closing price: N/A
Date announced: Nov. 5, 2020
Bayer/Asklepios BioPharmaceutical
Deal value: $2 billion (upfront)
Premium to previous closing price: N/A
Date announced: Oct. 26, 2020
Nestlé/Aimmune Therapeutics
Deal value: $2 billion
Premium to previous closing price: 174%
Date announced: Aug. 31, 2020
Servier/Agios Pharmaceuticals’ oncology portfolio
Deal value: $1.8 billion (upfront)
Premium to previous closing price: N/A
Date announced: Dec. 21, 2020
(News from Fierce Pharma)